| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Jouko Miettunen | Q38640161 |
| Hannu Koponen | Q44571789 | ||
| Johanna Löhönen | Q60673489 | ||
| Matti Isohanni | Q64539324 | ||
| P2093 | author name string | Johanna Koskinen | |
| P2860 | cites work | Reasons for increased substance use in psychosis | Q22252274 |
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Clinical signs of cerebellar dysfunction in schizophrenia, alcoholism, and their comorbidity | Q28201108 | ||
| Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review | Q28238516 | ||
| Cannabis and schizophrenia. A longitudinal study of Swedish conscripts | Q28283322 | ||
| Methods for analysis of skewed data distributions in psychiatric clinical studies: working with many zero values | Q33204400 | ||
| Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes | Q33586386 | ||
| Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study | Q33962711 | ||
| Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden | Q34201663 | ||
| Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective | Q34509505 | ||
| Lifetime prevalence of psychotic and bipolar I disorders in a general population | Q34596831 | ||
| Schizophrenia in homeless persons: a systematic review of the literature | Q34680581 | ||
| Effects of cannabis use on outcomes of psychotic disorders: systematic review | Q34870543 | ||
| Alcohol and cannabis use in Urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. | Q37045867 | ||
| Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. | Q37089103 | ||
| Drug use and health among prison inmates | Q37125817 | ||
| Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia | Q38401669 | ||
| A descriptive study of pathways to care among hospitalized urban African American first-episode schizophrenia-spectrum patients | Q39751253 | ||
| Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. | Q39754449 | ||
| Patterns, predictors and impact of substance use in early psychosis: a longitudinal study | Q39789560 | ||
| A comparative study on schizophrenic patients with dual diagnosis | Q43836245 | ||
| Substance abuse in hospitalized psychiatric patients | Q43949912 | ||
| Comorbidity of substance abuse and other psychiatric disorders in acute general psychiatric admissions: a study from Lebanon | Q44221615 | ||
| Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study | Q44264704 | ||
| The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse | Q44395755 | ||
| Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences | Q44777019 | ||
| Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. | Q44827846 | ||
| Factors affecting hospital length of stay: is substance use disorder one of them? A study in a Greek public psychiatric hospital | Q45412490 | ||
| The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems | Q46772825 | ||
| Schizophrenic patients without neuropsychological deficits: subgroup, disease severity or cognitive compensation? | Q48468710 | ||
| Patterns of current and lifetime substance use in schizophrenia | Q48715154 | ||
| Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model | Q48771741 | ||
| The role of alcohol and drugs in homicides in England and Wales. | Q50786015 | ||
| Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. | Q51912807 | ||
| Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. | Q51915513 | ||
| Early adolescent cannabis exposure and positive and negative dimensions of psychosis. | Q51937432 | ||
| Reasons for the diagnostic discordance between clinicians and researchers in schizophrenia in the Northern Finland 1966 Birth Cohort. | Q51948317 | ||
| Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services. | Q51958090 | ||
| Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. | Q51988878 | ||
| The reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in psychosis. | Q52290509 | ||
| Prevalence and correlates of comorbidity 8 years after a first psychotic episode. | Q53803702 | ||
| Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. | Q55056971 | ||
| Substance use in a population-based clinic sample of people with first-episode psychosis | Q57773718 | ||
| Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity | Q59668672 | ||
| Is Substance Abuse in Schizophrenia Related to Impulsivity, Sensation Seeking, or Anhedonia? | Q59668692 | ||
| Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes | Q60445926 | ||
| Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups | Q73649260 | ||
| Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients | Q73828005 | ||
| The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia | Q73927876 | ||
| Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects | Q73941963 | ||
| Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up | Q79927255 | ||
| Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample | Q80578981 | ||
| Comorbid substance-use in schizophrenia: relation to positive and negative symptoms | Q83915156 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| patient | Q181600 | ||
| schizophrenia | Q41112 | ||
| P304 | page(s) | 1115-1130 | |
| P577 | publication date | 2009-04-22 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis | |
| P478 | volume | 36 |
| Q89512663 | A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis |
| Q40910972 | A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder. |
| Q36364218 | A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches |
| Q39886298 | A comparison of the cumulative incidence and early risk factors for psychotic disorder in young adults in the Northern Finland Birth Cohorts 1966 and 1986. |
| Q21260309 | A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies |
| Q35529636 | A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia |
| Q58711366 | Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia |
| Q42676081 | Acute memory and psychotomimetic effects of cannabis and tobacco both 'joint' and individually: a placebo-controlled trial |
| Q35955940 | Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample |
| Q92953946 | Antecedents, Behaviours, and Court Case Characteristics and Their Effects on Case Outcomes in Litigation for Persons with Schizophrenia |
| Q38618558 | Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review |
| Q40639608 | Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study |
| Q38402859 | Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study |
| Q52600030 | Associations between adolescent cannabis use and brain structure in psychosis. |
| Q36651040 | Behavioral interventions for antipsychotic induced appetite changes |
| Q37980570 | Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness |
| Q37147730 | Cannabis Use and Associated Harms among Schizophrenia Patients in a Nigerian Clinical Setting: A Case-Control Study |
| Q33898124 | Cannabis Use and Dependence among French Schizophrenic Inpatients |
| Q94503123 | Cannabis Use in Inpatients With Schizophrenia Spectrum Disorders at a Community Hospital |
| Q38950359 | Cannabis and development of dual diagnoses: A literature review |
| Q90626055 | Cannabis and mental illness: a review |
| Q34398604 | Cannabis controversies: how genetics can inform the study of comorbidity |
| Q39126835 | Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. |
| Q33834127 | Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis |
| Q33985743 | Cannabis use disorders in schizophrenia: effects on cognition and symptoms |
| Q38569243 | Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. |
| Q41498847 | Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences |
| Q55691865 | Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Tr |
| Q58112202 | Changing characteristics of forensic psychiatric patients in Ontario: a population-based study from 1987 to 2012 |
| Q35534902 | Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q41040248 | Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis |
| Q38700007 | Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. |
| Q47749243 | Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study |
| Q92541706 | Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study |
| Q36621023 | Does change in cannabis use in established psychosis affect clinical outcome? |
| Q48722624 | Does giving up substance use work for patients with psychosis? A systematic meta-analysis |
| Q58605790 | Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people |
| Q47739996 | Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls |
| Q34128935 | Effects of cannabis use on age at onset in schizophrenia and bipolar disorder |
| Q98948596 | Exploring Phenotypic and Genetic Overlap Between Cannabis Use and Schizotypy |
| Q47754496 | Factor structure of the Cannabis Experiences Questionnaire in a first-episode psychosis sample. |
| Q24289498 | Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings |
| Q92826769 | Genome-wide association study implicates CHRNA2 in cannabis use disorder |
| Q30371361 | Habituation of the startle reflex depends on attention in cannabis users. |
| Q35213673 | How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library |
| Q44284126 | Inadequate fruit and vegetable intake in people with psychosis. |
| Q58763378 | Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function |
| Q91515857 | Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders |
| Q38739013 | Introduction of a drug-detection dog programme in mental health inpatient units: A mixed-methods study of consumer, staff, and carers' perceptions. |
| Q36148454 | Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study |
| Q47595582 | Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series |
| Q33762494 | Neurocognitive functioning of individuals with schizophrenia: using and not using drugs |
| Q33901507 | Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use |
| Q38949040 | New Clinically Relevant Findings about Violence by People with Schizophrenia |
| Q40600955 | Opioid abuse and hospitalization rates in patients with schizophrenia |
| Q37309718 | Peripheral endocannabinoid system dysregulation in first-episode psychosis |
| Q94562544 | Persistent cannabis use as an independent risk factor for violent behaviors in patients with schizophrenia |
| Q47566397 | Perspectives of cannabis use in the life experience of men with schizophrenia |
| Q38680307 | Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. |
| Q39577163 | Predictors of community functioning in schizophrenia and substance use disorder patients |
| Q37705255 | Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams |
| Q45165394 | Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal |
| Q37765631 | REVIEW: Genome-wide findings in schizophrenia and the role of gene-environment interplay. |
| Q33751954 | Reasons for illicit drug use in people with schizophrenia: Qualitative study |
| Q36945634 | Reduced Brain Cannabinoid Receptor Availability in Schizophrenia |
| Q50624456 | Relationship between tobacco and cannabis use status in outpatients with schizophrenia. |
| Q37244113 | Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia |
| Q30375488 | Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia. |
| Q35301038 | Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study. |
| Q50716139 | Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. |
| Q41437823 | Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study |
| Q34531537 | The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability |
| Q48273932 | The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions |
| Q47895252 | The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay |
| Q35563620 | The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document |
| Q34809059 | The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study |
| Q50562471 | The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. |
| Q45737010 | The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis |
| Q35096533 | The impact of cannabis use on clinical outcomes in recent onset psychosis. |
| Q33641039 | The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample |
| Q37061404 | The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study |
| Q55397242 | Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. |
| Q37381132 | Trajectory of adolescent cannabis use on addiction vulnerability |
| Q38639956 | Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. |
| Q37411782 | Walking the fine line: self-reported reasons for substance use in persons with severe mental illness |
| Q38001055 | Yoga in schizophrenia: a systematic review of randomised controlled trials |
Search more.